Moreover, through clinical approved drugs screening, we found Cepharanthine and Glucosamine were able to significantly inhibit viral RNA mimic poly (I:C)-induced the upregulation of ACE2, IL1β, and NF-κB downstream inflammatory cytokines, suggesting the potential application of these 2 drugs in the clinical treatment of COVID-19. The gene discussed is IL1B; the disease is COVID-19.